A Mutation in DOK7 in Congenital Myasthenic Syndrome Forms Aggresome in Cultured Cells, and Reduces DOK7 Expression and MuSK Phosphorylation in Patient-derived IPS Cells
Overview
Authors
Affiliations
At the neuromuscular junction, the downstream of tyrosine kinase 7 (DOK7) enhances the phosphorylation of muscle-specific kinase (MuSK) and induces clustering of acetylcholine receptors (AChRs). We identified a patient with congenital myasthenic syndrome (CMS) with two heteroallelic mutations in DOK7, c.653-1G>C in intron 5 and c.190G>A predicting p.G64R in the pleckstrin homology domain. iPS cells established from the patient (CMS-iPSCs) showed that c.653-1G>C caused in-frame skipping of exon 6 (120 bp) and frame-shifting activation of a cryptic splice site deleting seven nucleotides in exon 6. p.G64R reduced the expression of DOK7 to 10% of wild-type DOK7, and markedly compromised AChR clustering in transfected C2C12 myotubes. p.G64R-DOK7 made insoluble aggresomes at the juxtanuclear region in transfected C2C12 myoblasts and COS7 cells, which were co-localized with molecules in the autophagosome system. A protease inhibitor MG132 reduced the soluble fraction of p.G64R-DOK7 and enhanced the aggresome formation of p.G64R-DOK7. To match the differentiation levels between patient-derived and control induced pluripotent stem cells (iPSCs), we corrected c.190G>A (p.G64R) by CRISPR/Cas9 to make isogenic iPSCs while retaining c.653-1G>C (CMS-iPSCsCas9). Myogenically differentiated CMS-iPSCs showed juxtanuclear aggregates of DOK7, reduced expression of endogenous DOK7 and reduced phosphorylation of endogenous MuSK. Another mutation, p.T77M, also made aggresome to a less extent compared with p.G64R in transfected COS7 cells. These results suggest that p.G64R-DOK7 makes aggresomes in cultured cells and is likely to compromise MuSK phosphorylation for AChR clustering.
Wang Q, Cui C, Zhang N, Lin W, Chai S, Chow S J Orthop Translat. 2024; 46:91-102.
PMID: 38817243 PMC: 11137388. DOI: 10.1016/j.jot.2024.03.007.
Ohkawara B, Tomita H, Inoue T, Zhang S, Kanbara S, Koshimizu H Neurotherapeutics. 2024; 21(2):e00318.
PMID: 38233267 PMC: 10963930. DOI: 10.1016/j.neurot.2024.e00318.
Long-term muscle-specific overexpression of DOK7 in mice using AAV9-tMCK-DOK7.
Huang Y, Crick H, Chaytow H, van der Hoorn D, Alhindi A, Jones R Mol Ther Nucleic Acids. 2023; 33:617-628.
PMID: 37637210 PMC: 10457688. DOI: 10.1016/j.omtn.2023.07.036.
Ohno K, Ohkawara B, Shen X, Selcen D, Engel A Int J Mol Sci. 2023; 24(4).
PMID: 36835142 PMC: 9961056. DOI: 10.3390/ijms24043730.
Du P, Liu T, Luo P, Li H, Tang W, Zong S Arch Toxicol. 2023; 97(4):1147-1162.
PMID: 36800006 DOI: 10.1007/s00204-023-03457-9.